KR970705387A - 자궁내막암의 억제 방법(methods of inhibiting endometrial cancer) - Google Patents

자궁내막암의 억제 방법(methods of inhibiting endometrial cancer)

Info

Publication number
KR970705387A
KR970705387A KR1019970701095A KR19970701095A KR970705387A KR 970705387 A KR970705387 A KR 970705387A KR 1019970701095 A KR1019970701095 A KR 1019970701095A KR 19970701095 A KR19970701095 A KR 19970701095A KR 970705387 A KR970705387 A KR 970705387A
Authority
KR
South Korea
Prior art keywords
endometrial cancer
compound
methods
inhibiting endometrial
inhibiting
Prior art date
Application number
KR1019970701095A
Other languages
English (en)
Korean (ko)
Inventor
수잔 마가렛 보스
Original Assignee
스트링거 피터 지
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스트링거 피터 지, 일라이 릴리 앤드 캄파니 filed Critical 스트링거 피터 지
Publication of KR970705387A publication Critical patent/KR970705387A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1019970701095A 1994-08-22 1995-08-21 자궁내막암의 억제 방법(methods of inhibiting endometrial cancer) KR970705387A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29385394A 1994-08-22 1994-08-22
US08/293,853 1994-08-22
PCT/US1995/010651 WO1996005833A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer

Publications (1)

Publication Number Publication Date
KR970705387A true KR970705387A (ko) 1997-10-09

Family

ID=23130867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701095A KR970705387A (ko) 1994-08-22 1995-08-21 자궁내막암의 억제 방법(methods of inhibiting endometrial cancer)

Country Status (17)

Country Link
EP (1) EP0777476A4 (ja)
JP (1) JPH10504824A (ja)
KR (1) KR970705387A (ja)
AU (1) AU688112B2 (ja)
CA (1) CA2198119A1 (ja)
CZ (1) CZ51897A3 (ja)
FI (1) FI970717A0 (ja)
HU (1) HUT76890A (ja)
IL (1) IL115022A (ja)
MX (1) MX9701327A (ja)
MY (1) MY113757A (ja)
NO (1) NO970783D0 (ja)
NZ (1) NZ292017A (ja)
RU (1) RU2161964C2 (ja)
TW (1) TW404834B (ja)
WO (1) WO1996005833A1 (ja)
ZA (1) ZA956994B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN115825414B (zh) * 2023-01-09 2023-04-25 中国医学科学院北京协和医院 血液或尿液代谢标志物及其在子宫内膜癌早筛中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
AU6556194A (en) * 1993-04-07 1994-10-24 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists
DK0652004T3 (da) * 1993-10-15 2002-09-02 Lilly Co Eli Fremgangsmåder til behandling af resistente neoplasmer
CZ52297A3 (en) * 1994-08-22 1997-08-13 Lilly Co Eli Pharmaceutical preparation for inhibiting primary endometrial hyperplasia
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Also Published As

Publication number Publication date
TW404834B (en) 2000-09-11
IL115022A0 (en) 1998-06-15
MY113757A (en) 2002-05-31
IL115022A (en) 2000-07-31
AU688112B2 (en) 1998-03-05
WO1996005833A1 (en) 1996-02-29
AU3370095A (en) 1996-03-14
JPH10504824A (ja) 1998-05-12
CZ51897A3 (en) 1997-06-11
NO970783L (no) 1997-02-20
EP0777476A1 (en) 1997-06-11
CA2198119A1 (en) 1996-02-29
NZ292017A (en) 2000-07-28
FI970717A (fi) 1997-02-20
MX9701327A (es) 1997-05-31
ZA956994B (en) 1997-02-21
NO970783D0 (no) 1997-02-20
RU2161964C2 (ru) 2001-01-20
HUT76890A (en) 1997-12-29
EP0777476A4 (en) 1999-06-23
FI970717A0 (fi) 1997-02-20

Similar Documents

Publication Publication Date Title
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950010893A (ko) 자궁내막증 억제 방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950017949A (ko) 벤조티오펜 화합물과 수용성 사이클로덱스트린의 수용성 내포착물, 및 그의 약학제제 및 제조 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR970705384A (ko) 골 보철 파손의 억제 방법(methods for inhibiting bone prosthesis degeneration)
KR970707108A (ko) 항염증제로 유용한, 복소환부를 갖는 디-t-부틸페놀 화합물(DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application